Last edition
News about
TempraMed Secures South Korea Patent for VIVI Box Medication Storage Technology
TempraMed Technologies Ltd, a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, announced that it has been granted an additional allowed patent in South Korea, issued under Korean Patent Application No. 10-2021-7011422.
EU Approves AstraZeneca's Saphnelo for Subcutaneous Self-Administration in Lupus
AstraZeneca has received approval from the European Commission for subcutaneous self-administration of Saphnelo (anifrolumab) using a pre-filled pen for adult patients with systemic lupus erythematosus, in addition to standard therapy.
XOMA Royalty to Acquire Generation Bio
The acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna.
Alphyn Closes USD 25 Million Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Alphyn has closed an oversubscribed USD 25 million Series B financing round to support its dermatology pipeline, including a global Phase II (b) trial in atopic dermatitis and a Phase II clinical programme in molluscum contagiosum.
Vor Bio Announces USD 150 Million Private Placement
Vor Bio has announced a private placement expected to raise approximately USD 150 million in gross proceeds before expenses, with the transaction anticipated to close on or about 18 December, 2025, subject to customary closing conditions.
Adaptive Biotechnologies Signs Two Immune Receptor Licensing Deals with Pfizer
Adaptive Biotechnologies has signed two immune receptor licensing agreements with Pfizer, covering a T-Cell Receptor (TCR) discovery collaboration in rheumatoid arthritis and access to Adaptive’s proprietary TCR-antigen datasets for immunology R&D.
PharmAla Biotech Australia Ties Up with UK CDMO to Manufacture ALA-002
PharmAla Biotech Australia has contracted a UK-based CDMO to manufacture the drug substance for ALA-002, its patented non-racemic MDMA formulation, ahead of planned phase 2a/2b clinical trials for social anxiety disorder expected to begin in 2026.
Dyadic Applied BioSolutions has entered into a commercial partnership with Opes to accelerate adoption of its recombinant growth factors and media proteins, leveraging Opes’ market presence in Europe, Israel and Asia, while retaining Dyadic’s ability to sell directly and engage additional partners, globally.
Lupin's Climate Targets Across All Emission Scopes Validated by SBTi
Global pharmaceutical major Lupin Limited has announced that its greenhouse gas emissions reduction targets have been officially validated by the Science Based Targets initiative. The validation covers Scope 1, Scope 2 and Scope 3 emissions, aligning Lupin’s climate strategy with the Paris Agreement goal of limiting global temperature rise to 1.5°C.
GENESIS Pharma Secures Exclusive Rights to Commercialise Donidalorsen Across 14 CEE Markets
GENESIS Pharma, a regional biopharma company specialising in the commercialisation of innovative medicines in Central and Eastern Europe (CEE), has entered into an exclusive agreement with Otsuka Pharmaceutical Europe Ltd., the European arm of Otsuka Pharmaceutical Co., Ltd., for the distribution and commercialisation of donidalorsen.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy